Amneal Gets FDA Approval for Infection Treatment; Shares Rise

Amneal Pharmaceuticals says FDA approved abbreviated new drug application for a treatment of certain infections. Shares rose as much as 6% in post-market trading.

• The product, ciprofloxacin and dexamethasone otic suspension, is indicated to treat infections caused by susceptible isolates of the designated microorganisms in Acute Otitis Externa in pediatric, adult, and elderly patients due to staphylococcus aureus and pseudomonas aeruginosa

To view the source of this information, click here

To contact the reporter on this story:
Jim Silver in New York at jsilver@bloomberg.net

To contact the editor responsible for this story:
Sunil Kesur at skesur@bloomberg.net

© 2024 Bloomberg L.P. ...